Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.44 USD | +1.74% | -1.38% | +41.54% |
Mar. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
Mar. 14 | Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 328.8 | 191.1 | 178.7 | 199.8 | 410.9 | - | - |
Enterprise Value (EV) 1 | 328.8 | 191.1 | 178.7 | 199.8 | 228.7 | 353.3 | 347.6 |
P/E ratio | -6 x | -3.66 x | -3.01 x | -5.42 x | -5.23 x | -3.07 x | -3.02 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | 7.96 x |
EV / Revenue | - | - | - | - | - | - | 6.74 x |
EV / EBITDA | - | - | -4.94 x | -4.82 x | -3.56 x | -4.69 x | - |
EV / FCF | - | - | -4,892,455 x | - | - | - | - |
FCF Yield | - | - | -0% | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 15,356 | 17,710 | 43,269 | 43,906 | 63,800 | - | - |
Reference price 2 | 21.41 | 10.79 | 4.130 | 4.550 | 6.440 | 6.440 | 6.440 |
Announcement Date | 3/4/21 | 3/25/22 | 3/14/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 51.6 |
EBITDA 1 | - | - | -36.21 | -41.45 | -64.17 | -75.37 | - |
EBIT 1 | -42.8 | -50.46 | -36.53 | -41.76 | -82.03 | -119.9 | -158.8 |
Operating Margin | - | - | - | - | - | - | -307.75% |
Earnings before Tax (EBT) 1 | -42.48 | -50.64 | -35.36 | -36.95 | -80.8 | -160 | -158.8 |
Net income 1 | -42.48 | -50.64 | -35.36 | -36.95 | -79.88 | -144.3 | -172.8 |
Net margin | - | - | - | - | - | - | -334.88% |
EPS 2 | -3.570 | -2.950 | -1.370 | -0.8400 | -1.232 | -2.097 | -2.135 |
Free Cash Flow | - | - | -36.53 | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 3/4/21 | 3/25/22 | 3/14/23 | 3/14/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | - | - | - | - | - | - | - | -14.08 | -12.49 | -14.24 | -17.01 | - | - |
EBIT 1 | -16.73 | -9.086 | -8.887 | -8.687 | -8.513 | -10.44 | -7.637 | -9.62 | -10.34 | -14.16 | -15.3 | -18.45 | -23.3 | -26.15 | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -16.8 | -9.134 | -8.943 | -8.667 | -8.32 | -9.425 | -6.526 | -8.366 | -9.064 | -12.99 | -14.7 | -17.85 | -22.7 | -25.55 | - |
Net income 1 | -16.8 | -9.134 | -8.943 | -8.667 | -8.32 | -9.425 | -6.526 | -8.366 | -9.064 | -12.99 | -15.2 | -18.2 | -22.5 | -25.6 | -30 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.9200 | -0.5000 | -0.4900 | -0.4700 | -0.3700 | -0.2100 | -0.1500 | -0.1900 | -0.2100 | -0.2900 | -0.2350 | -0.2775 | -0.3400 | -0.3775 | -0.4450 |
Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/12/21 | 3/25/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/14/23 | 5/15/23 | 8/10/23 | 11/14/23 | 3/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | - | 182 | 57.6 | 63.3 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | -36.5 | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | -40.3% | - | -62.2% | -61.5% | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | 0.06 | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/4/21 | 3/25/22 | 3/14/23 | 3/14/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.54% | 411M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- LRMR Stock
- Financials Larimar Therapeutics, Inc.